会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 24. 发明公开
    • MODIFIED TOXINS
    • 修饰的毒素
    • EP2268297A1
    • 2011-01-05
    • EP08873133.6
    • 2008-12-15
    • Angelica Therapeutics, INC.
    • DAVIS, Claude, GeoffreyDATTA, DeepshikhaBAKER, Matthew, PaulKEEN, SimonRUST, Alyson, Jane
    • A61K38/16A61P37/06A61K39/395
    • C07K14/34A61K38/00C07K2319/035
    • The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a polypeptide toxophore from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope and at least one amino acid residue of at least one VLS motif of an unmodified native diphtheria toxin. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease.
    • 本申请涉及表现出降低的免疫原性和降低的与血管内皮或血管内皮细胞的结合的修饰毒素的组合物,由此降低血管渗漏综合征的发病率。 还提供了来自修饰的白喉毒素的多肽毒素,其中修饰在至少一个T细胞表位的至少一个氨基酸残基中。 另一个方面涉及来自修饰的白喉毒素的多肽的毒素,其中修饰在未修饰的天然白喉毒素的至少一个T细胞表位的至少一个氨基酸残基和至少一个VLS基序的至少一个氨基酸残基 。 另一方面涉及包含修饰的白喉毒素和作为细胞结合部分的非白喉毒素片段的融合蛋白。 另一方面涉及修饰的白喉毒素用于治疗恶性疾病或非恶性疾病的用途。